Clinical Trial Update: Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating vaccination with peptides from anti-apoptotic proteins in relapsed multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Vaccination with peptides from anti-apoptotic proteins

Snippet

Sponsor: Herlev Hospital | Conditions: Relapsed Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED